Sera Prognostics SERA
NASDAQ SERA
$2.14 +0.04 (+1.90%)
At close: Aug 21, 2026 · 4:00 PM EDT

Sera Prognostics (SERA) Net Income towards Common Stockholders (2020 - 2026)

Sera Prognostics' (SERA) quarterly Net Income towards Common Stockholders came in at -$10.9 million in Q1 2026, down 27.82% YoY from -$15.0 million in Q1 2025, and down 110.34% on a QoQ basis from -$5.2 million in Q4 2025.

Sera Prognostics (SERA) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Sera Prognostics (SERA) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$10.9 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 27.82% year-over-year to -$10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$41.1 million (down 19.74% YoY) and the FY2025 annual result came in at -$118.0 million, down 5.32% from the prior year.
  • Net Income towards Common Stockholders slipped to -$10.9 million in Q1 2026, from -$5.2 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$5.2 million in Q4 2025 to a low of -$12.7 million in Q3 2025.
  • A 5-year average of -$9.9 million and a median of -$10.4 million in 2022 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 70.51% — and 2025, when it jumped 41.05%.
  • Tracing SERA's Net Income towards Common Stockholders over 5 years: stood at -$10.4 million in 2022, then rose by 23.99% to -$7.9 million in 2023, then slipped by 10.39% to -$8.8 million in 2024, then jumped by 41.05% to -$5.2 million in 2025, then plunged by 110.34% to -$10.9 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$10.9 million (Q1 2026), -$5.2 million (Q4 2025), and -$12.7 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Abbott Laboratories 202.72 Bn 197.12 Bn 7.27 Bn 928.00 Mn
2 Stryker 126.42 Bn 122.94 Bn 4.50 Bn 1.28 Bn
3 Medtronic 119.75 Bn 110.53 Bn 6.41 Bn 1.26 Bn
4 Boston Scientific 74.13 Bn 73.60 Bn 3.85 Bn 907.00 Mn
5 Edwards Lifesciences 51.78 Bn 47.53 Bn 1.35 Bn 241.40 Mn
6 Dexcom 35.29 Bn 33.34 Bn 830.00 Mn 249.10 Mn
7 GE HealthCare Technologies 33.95 Bn 31.85 Bn 2.18 Bn 574.00 Mn
8 Koninklijke Philips 26.22 Bn 22.90 Bn 4.55 Bn 621.86 Mn
9 Steris 23.21 Bn 22.73 Bn 684.20 Mn 201.00 Mn
10 Sera Prognostics 108.53 Mn 108.53 Mn -20,000.00 -9.19 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -14.23 Mn
Mar 31, 2026 -10.86 Mn
Dec 31, 2025 -5.16 Mn
Sep 30, 2025 -12.65 Mn
Jun 30, 2025 -12.38 Mn
Mar 31, 2025 -8.50 Mn
Dec 31, 2024 -8.76 Mn
Sep 30, 2024 -8.29 Mn
Jun 30, 2024 -8.74 Mn
Mar 31, 2024 -8.92 Mn
Dec 31, 2023 -7.93 Mn
Sep 30, 2023 -7.83 Mn
Jun 30, 2023 -11.47 Mn
Mar 31, 2023 -11.35 Mn
Dec 31, 2022 -10.44 Mn
Sep 30, 2022 -11.21 Mn
Jun 30, 2022 -11.90 Mn
Mar 31, 2022 -12.45 Mn
Dec 31, 2021 -12.02 Mn
Sep 30, 2021 -9.88 Mn